Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chia-Chi Lin

Showing results (131-140 of 231) with videos related to

Pageof 24
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 31, 2015
Pathological stage after neoadjuvant chemoradiation and esophagectomy superiorly predicts survival in patients with esophageal squamous cell carcinomaChia-Chun Wang, Jason Chia-Hsien Cheng, Chiao-Ling Tsai, et al.
Investigational New Drugs|May 2, 2019
A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignanciesNoboru Yamamoto, Baek-Yeol Ryoo, Bhumsuk Keam, et al.
European Journal of Cancer (Oxford, England : 1990)|June 24, 2014
First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trialJames Chih-Hsin Yang, Jin Hyoung Kang, Tony Mok, et al.
The Oncologist|May 17, 2017
Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line GefitinibZong-Han Yao, Wei-Yu Liao, Chao-Chi Ho, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 27, 2019
Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatmentShao-Lun Lu, Feng-Ming Hsu, Chiao-Ling Tsai, et al.
European Journal of Cancer (Oxford, England : 1990)|July 7, 2019
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patientsZong-Han Yao, Wei-Yu Liao, Chao-Chi Ho, et al.
Plos One|August 26, 2022
Determinants of coronavirus disease 2019 infection by artificial intelligence technology: A study of 28 countriesHsiao-Ya Peng, Yen-Kuang Lin, Phung-Anh Nguyen, et al.
European Journal of Cancer (Oxford, England : 1990)|June 14, 2020
Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanomaLu Si, Xiaoshi Zhang, Sang Joon Shin, et al.
British Journal of Cancer|June 21, 2019
A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomasChia-Chi Lin, Hendrik-Tobias Arkenau, Sharon Lu, et al.
ACS Nano|November 30, 2020
A Solution Processable Dithioalkyl Dithienothiophene (DSDTT) Based Small Molecule and Its Blends for High Performance Organic Field Effect TransistorsChia-Chi Lin, Shakil N Afraj, Arulmozhi Velusamy, et al.
Pageof 24

Showing results (131-140 of 231) with videos related to

Sort By:
Pageof 24
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 31, 2015
Pathological stage after neoadjuvant chemoradiation and esophagectomy superiorly predicts survival in patients with esophageal squamous cell carcinomaChia-Chun Wang, Jason Chia-Hsien Cheng, Chiao-Ling Tsai, et al.
Investigational New Drugs|May 2, 2019
A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignanciesNoboru Yamamoto, Baek-Yeol Ryoo, Bhumsuk Keam, et al.
European Journal of Cancer (Oxford, England : 1990)|June 24, 2014
First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trialJames Chih-Hsin Yang, Jin Hyoung Kang, Tony Mok, et al.
The Oncologist|May 17, 2017
Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line GefitinibZong-Han Yao, Wei-Yu Liao, Chao-Chi Ho, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 27, 2019
Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatmentShao-Lun Lu, Feng-Ming Hsu, Chiao-Ling Tsai, et al.
European Journal of Cancer (Oxford, England : 1990)|July 7, 2019
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patientsZong-Han Yao, Wei-Yu Liao, Chao-Chi Ho, et al.
Plos One|August 26, 2022
Determinants of coronavirus disease 2019 infection by artificial intelligence technology: A study of 28 countriesHsiao-Ya Peng, Yen-Kuang Lin, Phung-Anh Nguyen, et al.
European Journal of Cancer (Oxford, England : 1990)|June 14, 2020
Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanomaLu Si, Xiaoshi Zhang, Sang Joon Shin, et al.
British Journal of Cancer|June 21, 2019
A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomasChia-Chi Lin, Hendrik-Tobias Arkenau, Sharon Lu, et al.
ACS Nano|November 30, 2020
A Solution Processable Dithioalkyl Dithienothiophene (DSDTT) Based Small Molecule and Its Blends for High Performance Organic Field Effect TransistorsChia-Chi Lin, Shakil N Afraj, Arulmozhi Velusamy, et al.
Pageof 24